New Antibody-Drug conjugate STRO-002 tested in advanced cancers
NCT ID NCT06238687
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deliver the drug directly to cancer cells. The main goals were to check safety, side effects, and how the drug moves through the body, as well as to get an early look at whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STRO-002 (an antibody-drug conjugate that combines a targeted antibody with a chemotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for advanced ovarian, endometrial, and other solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 19 participants, so results may not apply to larger populations. The drug may cause side effects or fail to shrink tumors effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China